Osteoporosis drugs: Risk of bone problems in jaw, thigh?
Medically reviewed on September 24, 2018
Certain types of osteoporosis drugs have been associated with an increased risk of two rare but serious problems — osteonecrosis of the jaw and an unusual type of fracture in the upper thigh bone (femur).
Osteonecrosis of the jaw develops when the jawbone fails to heal after a minor injury, such as getting a tooth pulled. An impending atypical femoral fracture can cause pain in the thigh or groin that begins subtly and gradually worsens. It sometimes develops in both legs at once. If untreated, a complete fracture of the femur requiring surgery can occur even with normal weight-bearing.
Bisphosphonates — such as alendronate (Fosamax, Binosto), risedronate (Actonel, Atelvia), ibandronate (Boniva) and zoledronic acid (Reclast, Zometa) — and denosumab (Prolia, Xgeva) have been linked to osteonecrosis of the jaw and atypical femoral fractures.
The risk appears to increase with the length of time the drugs are taken.
In addition to treating osteoporosis, bisphosphonates and denosumab are also used to treat cancer that has spread to the bone. The risk of osteonecrosis of the jaw is much greater for people taking higher doses of these drugs to treat cancer than it is for people who are simply treating osteoporosis.